Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 2, 2012, Pages 176-182

  Shelbaya, S ^a   Amer, H ^a   Seddik, S ^a   Allah, A A ^a   Sabry, I M ^a   Mohamed, T ^a   El Mosely, M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Diabetic nephropathy; Hs CRP and IL6; Type 1 DM

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADOLESCENT; ADULT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; ENZYME ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LABORATORY TEST; MALE; MICROALBUMINURIA; REVIEW; RISK ASSESSMENT; ALBUMINURIA; ARTICLE; BLOOD; DIABETIC NEUROPATHY; METABOLISM; PHYSIOLOGY;

ADOLESCENT; ADULT; ALBUMINURIA; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERLEUKIN-6; LIPIDS; MALE; YOUNG ADULT;

EID: 84859486300     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. AMERICAN DIABETES ASSOCIATION. Nephropathy in diabetes (Position Statement). Diabetes Care 2004;27(Suppl. 1):S79-S83.
2. SKUNDRIC DS, LISAK RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Exp Diabesity Res 2003;4:303-312. (Pubitemid 38035569)
3. WILLIAMS MD, NADLER JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007;7:242-248. (Pubitemid 46951922)
4. SANTHANAM U, RAY A, SEHGAL PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci 2003;88:7605-7609.
5. JONES CA, LEESE G P, KERR S, BESTWICK K, ISHERWOOD DI, VORA J P, HUGHES DA, SMITH C. Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus. Arch Dis Child 1998;78:518-523. (Pubitemid 28274692)
6. VIGUSHIN, DM, PEPYS MB, HAWKINS PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1998;91:1351-1357.
7. PEPYS MB, HERBERT J, HUTCHINSON WL, TENNENT GA, LACHMANN HJ, GALLIMORE JR, LOVAT LB, BARTFAI T, ALANINE A, HERTEL C, HOFFMANN T, JAKOB-ROETNE R, NORCROSS RD, KEMP JA, YAMAMURA K, SUZUKI M, TAYLOR GW, MURRAY S, THOMPSON D, PURVIS A, KOLSTOE S, WOOD S P, HAWKINS PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417(6886):254-259. (Pubitemid 34534701)
8. SIEDAL J. Total cholesterol determination by pap method. Clin Chem 1983;29:1057.
9. OCKENE IS, CHIRIBOGA DE, STANEK EJ 3RD, HARMATZ MG, NICOLOSI R, SAPERIA G, WELL AD, FREEDSON P, MERRIAM PA, REED G, MA Y, MATTHEWS CE, HEBERT JR. Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med 2004;164:863-870. (Pubitemid 38520627)
10. FRIEDEWALD WT. Calculation of LDL cholesterol. Clin Chem 1972;18:499.
11. BAZARI H. Approach to the patient with renal disease. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier: chap 115, 2007.
12. DOETSCH, K, GADSDEN, RH. Further on urinary protein determination. Letter to the Editor. Clin Chem 1984;20:1384.
13. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY R P, HENNEKENS CH. Inflammation, aspirin, and the risk of cardiovascular events in apparently healthy men. N Engl J Med 1997;336:973-979. (Pubitemid 27152782)
14. DI CESARE PE, CHANG E, PRESTON C F, LIU CJ. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty. J Bone Joint Surg Am 2005;87:1921-1927. (Pubitemid 41279121)
15. PICARDI A, VALORANI MG, VESPASIANI GENTILUCCI U, MANFRINI S, CIOFINI O, CAPPA M, GUGLIELMI C, POZZILLI P; IMDIAB Group. Raised C-reactive protein levels in patients with recent onset type 1 diabetes. Diabetes Metab Res Rev 2007;23:211-214. (Pubitemid 46437846)
16. COULON J, WILLEMS D, DORCHY H. Increase in C-reactive protein plasma levels during diabetes in infants and young adults. Presse Med 2006;34:89-93.
17. ALEXANDRAKI KI, PIPERI C, ZIAKAS PD, APOSTOLOPOULOS N V, MAKRILAKIS K, SYRIOU V, DIAMANTI-KANDARAKIS E, KALTSAS G, KALOFOUTIS A. Cytokine secretion in long-standing diabetes mellitus Type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol 2008;28:314-321.
18. PICCIRILLO LJ, GONÇALVES M F, CLEMENTE EL, GOMES MB. Markers of inflammation in type 1 diabetic patients. Arq Bras Endocrinol Metab 2004;48:253-260.
19. SARAHEIMO M, TEPPO AM, FORSBLOM C, FAGERUDD J, GROOP PH. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients, Diabetologia 2003;46:1402-1407. (Pubitemid 37297211)
20. SCHALWIJK CG, POLAND D C W, VAN DIJK W. plasma concentration of C-reactive protein is increased in type 1 diabetic patients without macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-357. (Pubitemid 29111443)
21. SCHWEDLER S, SCHINZEL R, VAITH P, WANNER C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 2001;78:S32-36. (Pubitemid 32144066)
22. SCHWAB KO, DOERFER J, HECKER W, GRULICH-HENN J, WIEMANN D, KORDONOURI O, BEYER P, HOLL R W. DPV Initiative of the German Working Group for Pediatric Diabetology Spectrum and prevalence of atherogenic risk factors in 27, 358 children, adolescents, and young adults with type 1 diabetes. Cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006;29:218-225. (Pubitemid 44106495)
23. ONAT A, SANSOY V, YILDIRIM B, KELEŞ I, UYSAL O, HERGENÇ G. C-reactive protein and coronary heart disease in western Turkey. Am J Cardiol 2001;88:601-607. (Pubitemid 32834041)
24. MAHADIK SR, DEO SS, MEHTALIA SD. Association of adiposity, inflammation and atherosclerosis: The role of adipocytokines and CRP in Asian Indian subjects. Metabol Syndrome Relat Dis 2008;6:121.
25. KARLSSON FARESJO MG, ERNERUDH J, LUDVIGSSON J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004;59:517-526. (Pubitemid 38725562)
26. DOGAN Y, AKARSU S, USTUNDAG B, YILMAZ E, GURGOZE MK. Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children. Mediat Inflamm 2006;2006:59206.
27. HANSEN TK, THIEL S, KNUDSEN ST, GRAVHOLT CH, CHRISTIANSEN JS, MOGENSEN CE, POULSEN PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003;88:4857-4861. (Pubitemid 37357536)
28. SCHRAM MT, CHATURVEDI N, SCHALKWIJK C, GIORGINO F, EBELING P, FULLER JH, STEHOUWER CD. EURODIAB Prospective Complications Study. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003;26:2165-2173. (Pubitemid 41184269)
29. FOLSOM AR, PANKOW JS, TRACY R P, ARNETT DK, PEACOCK JM, HONG Y, DJOUSSÉ L, ECKFELDT JH; Investigators of the NHBLI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001;88:112-117. (Pubitemid 32607694)
30. HALLER H, SCHATZ DG. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. N Engl J Med 2008;310:356-360.
31. TARGER G, ZENARI L, BERTOLINI L, MUGGEO M, ZOPPINI G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001;24:956-957. (Pubitemid 33636077)
32. CHOUDHARY N, AHLAWAT RS. Interleukin-6 and C - reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iranian J Kidney Dis 2008;2:72-79.
33. ERBAGCI AB, TARAKÇIOGLU M, COKUN Y, SIVASLI E, SIBEL NAMIDURU E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001;34:645-650. (Pubitemid 34159356)
34. GOMES MB, YEO CK, NAZAIMOON WM. Acute-phase proteins and microalbuminuria among patients with type 1 diabetes. Am J Kidney Dis Pract 2004;57:298.
35. AMINE R, TURNER C, VAN AKEN S, BAHU TK, WATTS A, LINDSELL DR, DALTON RN, DUNGER DB. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int 2005;68:1740-1749. (Pubitemid 43169918)
36. OLSEN BS, SJOLIE AK, HOUGAARD P, JOHANNESEN J, MARINELLI K, JACOBSEN BB, MORTENSEN HB; Danish Study Group of Diabetes in Childhood. The significance of the prepubertal diabetes duration for development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 2004;18:160-164. (Pubitemid 38622544)